Earnings call
Alembic Pharmaceuticals Q2 FY27 earnings call: Alembic Pharmaceuticals Limited's near-term objective in India is to reach market-level growth in the next 2 to 3 quarters
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
Near-term objective in India is to reach market-level growth in the next 2 to 3 quarters. The company spent about INR 250 crores on capex in the first half of the financial year ended 30th September 2026. Consolidated revenue was INR2,603 crores, growing 36% year-on-year in the quarter ended 30th September 2026. The company launched 3 products in the US market during the second quarter ended 30 th September, 2026; Alembic Pharmaceuticals Limited launched three generics, filed five ANDAs and received one approval during the quarter ended 30th September 2026. Net debt was INR1,236 crores in the first half of the financial year ended 30th September 2026, less than 1x of full-year EBITDA.
The numbers management gave
Results
- Consolidated revenue was INR2,603 crores, growing 36% year-on-year in the quarter ended 30th September 2026.
Show source
Consolidated revenue for the quarter was at INR2,603 crores, representing a growth of 36% Y-on-Y, driven by strong performances across all the business.
- Specialty portfolio grew about 200 basis points ahead of the Indian pharmaceutical market during the quarter ended 30th September 2026.
Show source
The specialty portfolio grew about 200 basis points ahead of the Indian pharmaceutical market during the quarter, and the overall growth gap versus the market has narrowed meaningfully.
- U.S. Generics revenue grew 72% year-on-year in the quarter ended 30th September 2026, supported by strong volume growth in the base portfolio and contributions from recent launches; the underlying business grew 23%.
Show source
The U.S. Generics delivered an exceptional quarter with revenue growing at 72% year-on- year.
- Consolidated gross margin expanded by 70 basis points year-on-year to 73.7% in the quarter ended 30th September 2026, benefiting from favorable product mix despite higher solvent costs and geopolitical headwinds.
Show source
Gross margin expanded by 70 basis points year-on-year to 73.7%, benefiting from favorable product mix despite higher solvent costs and geopolitical headwinds.
- R&D expenditure was 8% of revenue in the quarter ended 30th September 2026.
Show source
R&D expenditure for the quarter was 8% of revenue.
- Reported EBITDA grew 78% year-on-year and EBITDA margin expanded by around 520 basis points, from 17% in quarter 2 of last year to 22.2% in the quarter ended 30th September 2026; margin expansion reflected operating leverage in the core business, support from new launches and disciplined R&D expenditure while absorbing planned U.S. branded business investment.
Show source
Reported EBITDA grew 78%, while the EBITDA margin expanded by around 520 basis points from 17% in quarter 2 of last year to 22.2% in the current quarter.
Show 15 more statements
Results
- Profit before tax grew 95% year-on-year in the quarter ended 30th September 2026, and its effective tax rate was approximately 24%, compared with 18% in the previous year.
Show source
Profit before tax grew 95% year-on -year and effective tax rate for the quarter was approximately 24% compared with 18% in the previous year.
- The company moved to a normal tax rate of 25% in India effective from this financial year, while cash tax continues to be around 18.75% considering the available MAT credit.
Show source
As a reminder, we have moved to a normal tax rate of 25% in India effective from this financial year, while cash tax continues to be around 18.75% considering the available MAT credit.
- Consolidated revenue grew 31% year-on-year to INR 4,753 crores in the first half of the financial year ended 30th September 2026; reported EBITDA grew 51% and EBITDA margin improved by 255 basis points.
Show source
For the first half of the current financial year, consolidated revenue grew at 31% year-on - year to INR 4,753 crores, while reported EBITDA grew at 51% and EBITDA margin improved by 255 basis points.
- First-half PAT grew by about 50% in the half year ended 30th September 2026.
Show source
The first half PAT grew by about 50 %.
- Quarter 1 growth excluding bosutinib was in the mid-20s, driven by core business volume growth.
Show source
And just to reinforce the point, the quarter 1 growth was also excluding bosutinib was also in the mid- 20s, which reinforces the point that the core business, which is driven by volume growth continues.
- Increase in other expenses in the quarter ended 30th September 2026 was primarily driven by promotions and marketing expenses, including expenses related to U.S. branded business expansion.
Show source
On the other expenses, it's about -- the increase is primarily driven by certain promotions and marketing expenses.
- Expanded gross margin in the quarter ended 30th September 2026 resulted from absorbing increased transportation and other costs.
Show source
The gross margin that we expanded in the current quarter is actually a result of absorbing these costs that we are seeing in the transportation and other elements.
- Chronic segment divisions all grew year-on-year, contributing to better-than-IPM growth in quarter 2.
Show source
And what we are happy with the performance is also about the spread of performance across the divisions It's good to see that within the chronic segment, almost every division, all the divisions, in fact, have grown well year-on -year, which has contributed to better than IPM growth in quarter 2.
- The company saw volume-led growth this quarter apart from price and new products, with growth almost 50-50 between price and volume because of new launches, in the quarter ended 30th September 2026.
Show source
So directionally, I would say that it is almost 50- 50 between price and volume because new launches.
- Gross margins were within the guided 70% to 75% range, with solvent prices rising amid Middle East issues and product mix affecting gross margins.
Show source
We continue to operate within our guided range of 70% to 75% gross margins.
- Animal Health business grew 23% in the second quarter ended 30 th September, 2026.
Show source
So if you take the new launches out, so the base portfolio grew by 23% in the quarter.
- Employee cost increased year-on-year due to increments; headcount was holding as it was.
Show source
If you look at the employee cost, it's increased year-on- year.
- The company did not increase its India field force, while U.S. branded expansion in the field force contributed to increased employee cost, as planned and guided at the beginning of the year; the company was in line with expectations.
Show source
While the other element of employee cost-related increase is about the U.S. branded expansion that we are doing in the field force.
Money and capital
- Net debt was INR1,236 crores in the first half of the financial year ended 30th September 2026, less than 1x of full-year EBITDA.
Show source
Net debt remains comfortable at INR1,236 crores, which is less than 1x of full year EBITDA.
- Working capital is largely linked to longer collection cycles, especially on new U.S. launches, which would unwind progressively over the next few quarters.
Show source
The current working capital is largely linked to longer collection cycles, especially on the new U.S. launches, which would unwind progressively over the next few quarters.
What it expects ahead
What management expects
- Near-term objective in India is to reach market-level growth in the next 2 to 3 quarters.
Show source
In India, our near term objective is to reach market level growth in the next 2 to 3 quarters.
- The company now expects its U.S. business to grow up to 40% year-on-year for the full year, supported by base business volumes, new launches and continued scale-up of its specialty portfolio.
Show source
We now expect the U.S. business to grow up to 40% Y-on-Y for the full year, supported by base business volumes, new launches and continued scale-up of our specialty portfolio.
- The company raised its FY2 7 consolidated revenue growth guidance to about 20% to 25% from the mid-teens indicated last quarter, reflecting the stronger outlook for the U.S. and API and incorporating expected normalization of exclusivity-led sales.
Show source
Reflecting the stronger outlook for the U.S. and API, we are raising our FY2 7 consolidated revenue growth guidance to about 20% to 25% from the mid-teens indicated last quarter.
- The company expects its EBITDA margins of about 22% for the first half to continue in the second half and expects its margin profile to hold for the rest of the year.
Show source
So we don't see and that's also flowing through to the EBITDA margin, So I think you should look at the interplay how the gross margin to EBITDA is flowing through what we expect for the full year -- for the first half, we have about 22%EBITDA margins, which we expect to continue towards the second half as well.
- The company expects U.S. growth to continue, but says margins are difficult to project because product launches may be shared day-1 or FTF and will depend on how the market plays out.
Show source
I think the only thing we can project is moving forward, we expect the U.S. growth to continue.
- The company expects its gross margin to remain in the 70% to 75% range; business mix and the mix of new launches influence gross margin.
Show source
I think for now we expect it to be in that same range of 70% to 75%.
Show 18 more statements
What management expects
- U.S. branded portfolio caused a 150 to 200 basis point drag on a full year basis; the company expects this drag to end from the first half of next year and says it will not see the drag in FY2 8. Its goal was about 40 to 45 reps and it had about 30 or 35 at the time of the call.
Show source
So in terms of the spend, as Krishnan mentioned, the 150 to 200 basis point drag is on a full year basis.
- The company expects almost 30 products to be launched over the next 18 months or so, roughly a quarter of which will be a shared Day 1 or FTF opportunity. Alembic Pharmaceuticals Limited's existing pipeline supports a steady cadence of more than 30 launches over the next 18 months, with around a quarter comprising FTF or shared day-1 opportunities.
Show source
Our existing pipeline supports a steady cadence of more than 30 launches over the next 18 months with around a quarter of them comprising of FTF or shared day- 1 opportunities.
- The company expects its U.S. business to grow about 10% to 12% next year if all these launches pan out well.
Show source
I think it will be close to mid like about 10% to 12% kind of a growth definitely we can see next year if all these launches pan out well.
- The company would like to move toward EBITDA margins of about 20%.
Show source
Pranav Amin: Yes, we would like to go towards those kind of margins.
- The company expects growth in India to be driven by sharper execution in focused brands and priority markets, stronger presence in metros and a higher contribution from chronic and specialty therapies, while broadly maintaining the current field force scale.
Show source
We expect this to be driven by sharper execution in focused brands and priority markets, stronger Page 2of 13 Alembic Pharmaceuticals Limited November 04, 2026 presence in metros and a higher contribution from chronic and specialty therapies while broadly maintaining the current field force scale.
- The company expects its API business to deliver at least high teens growth for the year.
Show source
API business has also performed ahead of our expectations and is now expected to deliver at least high teens growth for the year.
- The company expects its India branded business to grow as per the market and get close to market growth to double digits, directionally aligning with market growth.
Show source
To reiterate, we expect India branded business to grow as per the market, get close to the market to double digits and directionally aligning with the market growth.
- The company expects its ex-U.S. business to grow at mid-teens.
Show source
We expect the ex-U.S. to grow at mid-teens.
- Bosutinib sales were far higher than expectations; its exclusivity runs until the end of November, with October and November remaining before exclusivity ends.
Show source
Pranav Amin: So bosutinib has done, yes, far higher than expectations or what we expect.
- The company expects acute to reach IPM level in the next couple of quarters and expects to be at IPM or higher over the next couple of quarters.
Show source
So over the next couple of quarters, we should be at IPM or higher.
- Immediate target is to bridge the gap versus overall market growth; acute is expected to take a couple of quarters to pan out, while chronic and specialty are already showing outcomes from the interventions.
Show source
And our -- I think the immediate target for us is to bridge the gap versus the market growth, which at an overall level is really visible.
- The company expects its U.S. branded business to break even by the end of this year or in the first half of next year, with month-on-month increases in activities and prescriptions.
Show source
And I believe that we will start breaking even in the first half of next -- by the end of this year or the first half of next year is when we'll break even.
- The company expects Pivya prescriptions to rise gradually and expects Pivya to contribute meaningfully by the start of the next year.
Show source
And in the second half, going to the -- by the start of the next year, we should see Pivya also contributing meaningfully.
- Existing pipeline supports a steady cadence of more than 30 launches over the next 18 months, with around a quarter comprising FTF or shared day-1 opportunities. Replaced by a later filing.
- Initial launches from Alembic Pharmaceuticals Limited and DifGen Pharmaceuticals’ expanded collaboration are expected from FY28, providing near-term revenue visibility and a platform for progressively increasing contribution to the US business as the broader portfolio is commercialised over the next few years.
Show source
Contributions are expected to begin from FY28 with the initial wave of launches providing near-term revenue visibility and a platform for progressively increasing contribution to the U.S. business as the portfolio is commercialized over the next few years.
- The company expects its acute portfolio to improve progressively over the coming quarters. Replaced by a later filing.
Show source
We expect the acute portfolio to improve progressively over the coming quarters as well.
- The company expects commercial execution interventions made over the last couple of quarters to sustain growth momentum over the next few quarters. Replaced by a later filing.
Show source
And – with the execution interventions, we expect that to sustain the growth momentum over the next few quarters.
- The company hopes to strengthen its portfolio in the next couple of quarters; it is focusing on sharper execution, focused brands and priority markets. Replaced by a later filing.
Show source
Right now, our portfolio is fine, but in the next couple of quarters, we hope to strengthen this as well.
What it is building and selling
Projects and capacity
- The company spent about INR 250 crores on capex in the first half of the financial year ended 30th September 2026.
Show source
We spent about INR 250 crores of capex.
- Major capex cycle is now behind it, and it is focusing on returns from the existing asset base through debottlenecking and incremental line additions without significant new greenfield investment.
Show source
With major capex cycle now behind us, our focus is on Page 4of 13 Alembic Pharmaceuticals Limited November 04, 2026 driving returns from the existing asset base through debottlenecking and incremental line additions without significant new greenfield investment.
- The company had a line shutdown in ophthalmics in Q4 of last year and Q1 of this year while increasing the line's capacity, causing a minor blip.
Show source
So that took a minor blip.
- The expanded collaboration reserves capacity for Alembic Pharmaceuticals Limited at DifGen Pharmaceuticals’ US facilities and provides a framework to progressively build US manufacturing capacity for select dosage forms.
Show source
The portfolio addresses an aggregate U.S. reference market of approximately $5 billion and also provides access to U.S. manufacturing capacity which can be reserved for us.
Demand and pricing
- The company has been able to get more prescriptions on NUVESSA and NUVETEST, which are existing products and have faster ramp-up than Pivya. Replaced by a later filing.
Segments
- The company launched 3 products in the US market during the second quarter ended 30 th September, 2026; Alembic Pharmaceuticals Limited launched three generics, filed five ANDAs and received one approval during the quarter ended 30th September 2026.
Show source
During the quarter, we launched three generics, filed five ANDAs and received one approval.
Show 11 more statements
Segments
- The company has about 4 products in its U.S. branded business portfolio, and all are contributing; Pivya is new in terms of new prescriptions, while NUVESSA and NUVETEST are already in the market, and changing prescription habits will take time, but the progress is as per expectations. Alembic Pharmaceuticals Limited has been able to get more prescriptions on NUVESSA and NUVETEST, which are existing products and have faster ramp-up than Pivya.
Show source
We've got about 4 products in the portfolio, and all of them are contributing.
- Alembic Therapeutics has about 4 products right now.
Show source
We just talked about Alembic Therapeutics, which has about 4 products right now.
- The expanded Alembic Pharmaceuticals Limited and DifGen Pharmaceuticals collaboration covers a portfolio of 20+ differentiated products across injectable, transdermal, ophthalmic, oral and other complex dosage forms addressing an aggregate reference market of ~US$5 billion.
Show source
The expanded partnership gives us access to a differentiated portfolio of over 20 products across transdermal patches, complex injectables, ophthalmics and other specialized dosage forms, including select first-to - file and day-1 opportunities.
- The company continues to evaluate companion animals, but has no firm strategy yet.
Show source
No firm strategy as yet, but we keep evaluating that.
- The company has coverage from insurance companies and Medicaid for its U.S. branded products.
Show source
So we've got all the Medicaid and all the coverages, and we've got all the coverage from the insurance companies as well as the Medicaid.
- The company had good market share in derm and considers derm a high EBITDA business, while derm is more competitive than ophthalmics.
Show source
Derm also, we managed to get good market share on the derm and it's a high EBITDA business for us.
- The company launched 3 products in the US market during the second quarter ended 30 th September, 2026. Replaced by a later filing.
Deals and partners
- The company has a licensing deal covering about 20-plus products from DifGen Pharmaceuticals, structured as a basket rather than a one-off deal, with profit sharing; DifGen generally manufactures, while Alembic manufactures some products.
Show source
S o we have tied up about 20-plus products from them.
- DifGen Pharmaceuticals has dosage forms in which Alembic Pharmaceuticals Limited is not present, which would add to Alembic's portfolio; the collaboration also includes a lot of FTFs and day-1 launches.
Show source
They also have a few other dosage forms, which we are not present in, which will give a good addition to our portfolio.
- The company pursues contract manufacturing in some facilities and capabilities, particularly in sterile and oncology, and has some contracts in place.
Show source
Pranav Amin: So we do pursue some contract manufacturing in some of our facilities and some of our capabilities, more so in the sterile and the oncology, and that is going on well, and I think we do have some contracts in place.
- In the Alembic Pharmaceuticals Limited and DifGen Pharmaceuticals collaboration, DifGen developed the products and manufactures most of them; Alembic Pharmaceuticals Limited may do some contract manufacturing and will do all the marketing and front end.
Show source
And all the marketing and front end will be done by us.
Risks, rules and outside factors
Outside factors
- Freight, forwarding and logistics costs for shipments from India to the U.S. and other markets increased year-on-year from the March quarter onwards because shipping lines and related costs expanded; transportation costs depend on where crude oil settles and shipping-line availability.
Show source
See, the other element that is included in the other expenses is also about the freight and forwarding cost, the logistics cost related to shipments from India to U.S. and other markets, which also saw a year-on- year increase from the March quarter onwards, right?
Everything else said on the call
What management stressed
- The company identified execution-led challenges across different territories, is working on field-force productivity in chronic portfolios, and said its metro coverage remains quite weak and needs improvement.
Show source
I think, in terms of the interventions, what we've seen is broadly I think it's been more execution-led challenges, firstly.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Rashmi Shetty: Okay. And is it something that whatever run rate what we were expecting for bosutinib, we have surpassed that growth also, I mean, quarterly sales also?
Answer, pranav amin
Pranav Amin: So bosutinib has done, yes, far higher than expectations or what we expect. It's -- as you know, we have exclusivity till end of November. So we've got 2 more months, which will be October, November, we'll see. What happens after that, I don't know. Let's see what the market shapes up as. But right now, it's done pretty well, and we're pretty happy with what we've achieved in the bosutinib.
Question
Rashmi Shetty: So the sales run rate is basically whatever is all expected, it is in that line only. So the new generic launches added the extra delta to the overall sales.
Answer, pranav amin
Pranav Amin: Yes, absolutely. And just to reinforce the point, the quarter 1 growth was also excluding bosutinib was also in the mid- 20s, which reinforces the point that the core business, which is driven by volume growth continues. Page 5of 13 Alembic Pharmaceuticals Limited November 04, 2026 Rashmi Shetty: And just on the India business, we were expecting that from the second half, we will be performing in line with the IPM.
Question
This guidance still holds, I mean, in the second half, would we expecting that for quarter 3 and quarter 4, it would normally recover and be in line with the IPM?
Answer, pranav amin
Pranav Amin: Yes, Rashmi. So I think what we're seeing in Q2 was an encouraging trend, especially we see the chronic outpaced IPM. Acute, yes, there are still some issues, but we're quite confident that hopefully, acute would also get to IPM level by the end -- in the next couple of quarters. So over the next couple of quarters, we should be at IPM or higher.
Question
Rashmi Shetty: Okay. And just on the cost front, your other expenses and staff costs, both quarter-on -quarter has gone up significantly. If you can comment on that part also? And how should we look at EBITDA margin for the full year? And what is the drag of Pivya for this quarter on the margin?
Answer, g krishnan
G. Krishnan: Yes. So too many questions loaded into that. Let me take it one by one. If you look at the employee cost, it's increased year-on- year. It has a combination of 2 parts. First is the increment that's come along. The headcount is holding as it is.
Answer, g krishnan
So we've not increased the field force in India. So it continues to remain constant. While the other element of employee cost-related increase is about the U.S. branded expansion that we are doing in the field force. So that has also contributed to the increase in employee cost, which is all part of the plan and the guidance that we had considered at the beginning of the year. So we are in line with what we expected. On the other expenses, it's about -- the increase is primarily driven by certain promotions and marketing expenses. And again, that also has an element of U.S. branded business expansion that we are doing.
Question
Rashmi Shetty: Yes. So I'm saying that this is the new base, right, for the subsequent quarters also, if you want to model in?
Answer, g krishnan
G. Krishnan: Yes. See, the other element that is included in the other expenses is also about the freight and forwarding cost, the logistics cost related to shipments from India to U.S. and other markets, which also saw a year-on- year increase from the March quarter onwards, right? So from March actually because of the shipping lines and the related costs expanding increasing. So that's also contributed to that. So it depends on where the crude oil settles in terms of transportation costs and the availability of shipping lines. But directionally speaking, if you look at how the margins are playing out, this is not something what we didn't expect. The gross margin that we expanded in the current quarter is actually a result of absorbing these costs that we are seeing in the transportation and other elements.
Answer, g krishnan
So we don't see and that's also flowing through to the EBITDA margin, So I think you should look at the interplay how the gross margin to EBITDA is flowing through what we expect for the full year -- for the first half, we have about 22%EBITDA margins, which we expect to continue towards the second half as well. So we should expect the margin profile to hold for the rest of the year.
Question
Rashmi Shetty: And how much would be the Pivya drag on it for the full year as well as for this quarter, how much we have seen?
Answer, pranav amin
Pranav Amin: So it's tough to say what the margins will be because when we launch these other products, I said fourth of our portfolio of 30 products that we have in the U.S. market, they will be either shared day-1 or FTF. There are 3, 4 which are FTF, then the rest. So it really depends how the market plays out. So it's tough to give a projection on that. I think the only thing we can project is moving forward, we expect the U.S. growth to continue.
Question
Kenil Mehta: We have a few products approved, which are going to expire. One is Toviaz and second is Uptravi, which are expiring in the next few quarters. So would we take into the numbers, we can launch and have a good number similar to this bosutinib in next few quarters run rate-wise for the U.S. business?
Answer, pranav amin
Pranav Amin: I actually don't like to comment on individual product-wise potential because there's too many - - Uptravi is a shared exclusivity on some of the strengths and the other one, it's a sole exclusivity. So it's tough to say. I think I'd leave it to all of you. I think you all should make the forecast, but I don't like to give a forecast because there's too many variables there.
Question
Kenil Mehta: And second question is as we are saying increasing improving growth of India business towards the IPM, as we see more growth coming, should we expect a little bump in our gross profit margin level due to it being better than the generic business over the next few quarters compared to earlier level?
Answer, g krishnan
G. Krishnan: Yes. So see, if you look at the gross margin, we have guided for a range of 70% to 75%, and we've been in that range for quite a few years. I think the mix of the business will have an interplay. The mix of new launches will have influence on the gross margin. I think for now we expect it to be in that same range of 70% to 75%. Page 7of 13 Alembic Pharmaceuticals Limited November 04, 2026 Kenil Mehta: Understood.
Question
And also on the Animal business side, there has been an improving growth in the companion animal space across India and other geographies. So should we see our portfolio getting little changes from the farm and feed supplement to a little companion side, which will lead to improving business dynamics? And also, are we expecting to go into the companion animal space in the Europe market -- U.S. and Europe market going forward?
Answer, pranav amin
Pranav Amin: I think if you see our Animal Health business, I think it's a very well-run Animal Health business and compared to pretty much most Animal Health businesses in India. If you say CAGR, we have a CAGR of over 20% over the last 5 to 7 years. I think we're doing very well in the space that we are in. We continue to evaluate other areas as well, including companion animals. No firm strategy as yet, but we keep evaluating that. So, let's see how it goes on. Right now, we're pretty confident about our growth with the existing business that we have.
Question
Kenil Mehta: Understood. And sir, last few quarters, you were telling about the contract manufacturing for the U.S. business for our plants. So what's the status on that? This quarter, we have a higher contract manufacturing share for our injectable unit?
Answer, pranav amin
Pranav Amin: So we do pursue some contract manufacturing in some of our facilities and some of our capabilities, more so in the sterile and the oncology, and that is going on well, and I think we do have some contracts in place.
Show 9 more questions
Question
Kenil Mehta: Okay. Is it on cost plus markup basis or a little bit of profit sharing?
Answer, pranav amin
Pranav Amin: No, this is pure contract manufacturing. If you can just get back in line, I think, because there's quite others...
Answer, g krishnan
G. Krishnan: I think Pranav touched upon it in the guidance, yes, Rahul. I think the commercial execution is reshaping and the intervention that's been made over the last couple of quarters is something which is playing out. And what we are happy with the performance is also about the spread of performance across the divisions It's good to see that within the chronic segment, almost every division, all the divisions, in fact, have grown well year-on -year, which has contributed to better than IPM growth in quarter 2. And – with the execution interventions, we expect that to sustain the growth momentum over the next few quarters. And our -- I think the immediate target for us is to bridge the gap versus the market growth, which at an overall level is really visible. Of course, the acute part is something that will take a Page 8of 13 Alembic Pharmaceuticals Limited November 04, 2026 couple of quarters to pan out. But the chronic is something -- chronic and specialty segment is something that we are already seeing the outcome of the interventions that's made.
Answer, g krishnan
So it should -- we expect that to sustain over the course of next few quarters as well.
Question
Rahul Jeewani: Sure, sir. And let's say, now with India business getting back to this track of double digit and we not meaningfully expanding the rep team, when do you think that, let's say, the improvement in the India business starts translating into a better base business profitability as well from a margin perspective?
Answer, pranav amin
Pranav Amin: Yes. I think that's a good question, Rahul. I think as I have mentioned in the past, our first priority is getting to the market rate at IPM, which we hope to be at in the next couple of quarters. Once that happens, you'll automatically see with the steady growth rate coming up and if we are not increasing our field force, that should lead to higher PCPM as well, and that will lead automatically to a little bit margin -- gradual margin improvement as we move around.
Question
Rahul Jeewani: Yes, sir. And on the U.S. business, you mentioned that the branded contribution during the quarter was 3% of overall U.S. sales. So if you can qualitatively comment in terms of how that has been versus the expectations which you would have put out for Pivya. So is it tracking largely in line? Or do we still need to ramp up as far as the branded business is concerned?
Answer, pranav amin
Pranav Amin: I think there's still a definite ramp-up required in this part of the business. We've got about 4 products in the portfolio, and all of them are contributing. Pivya is a new one in terms of new prescriptions, NUVESSA and NUVETEST, they're already in the market. So those prescriptions have been easier to get. But we believe that there is a lot of positivity in the market. I think -- but it's like a J-shaped curve. So it will be the prescription habits changing those will take a time, but it's as per our expectations.
Answer, pranav amin
And I believe that we will start breaking even in the first half of next -- by the end of this year or the first half of next year is when we'll break even. But the trends are positive. I think we're seeing a month-on -month increase in the activities and prescriptions as well.
Question
Rahul Jeewani: Sure, Pranav. And any, let's say, quantitative targets which you want to give out in terms of, let's say, 2 to 3 years out, what could potentially be the contribution from the branded business to our overall U.S. sales?
Answer, pranav amin
Pranav Amin: So I do have an internal target, but we haven't given a guidance on that as yet. I think let's wait until the end of the year. I think the next half will give you more confidence how the ramp-up is going on, and we'll be in a better position to give a guidance by then.
Question
So Pranav, if you can update a bit on what kind of channel access you have gained for the products which are in the market? And what kind of spend is currently ongoing? And do you need to put up more foot on the ground, like you have to do more hiring, etcetera, to achieve that breakeven in first half, next year or so? And just to clarify, this 150, 200 bps kind of drag from branded portfolio is on a full year basis, right?
Answer, pranav amin
Pranav Amin: Yes. So in terms of the spend, as Krishnan mentioned, the 150 to 200 basis point drag is on a full year basis. I also said that I expect that from first half of next year, this will be breakeven. So we won't see the drag in the next year, right? In FY2 8, we will not see the drag. In terms of feet on the ground, our goal was to get to about 40 to 45 reps. We're at about 30 or 35 right now.
Answer, pranav amin
Pranav Amin: You're right. So we've got all the Medicaid and all the coverages, and we've got all the coverage from the insurance companies as well as the Medicaid. So we're all well covered by all of them, and it's all on track.
Answer, pranav amin
Pranav Amin: Yes. Thanks, Maulik. I think, in terms of the interventions, what we've seen is broadly I think it's been more execution-led challenges, firstly. So we're just working on execution-led challenges at different territories. Number two is we're trying to see field force productivity, especially working on the chronic portfolios. Thirdly, what we're seeing our geographical spread, we were not -- and it's still -- we're still not 100% there, is our coverage from the metros is still quite weak. So we need to improve on that in terms of geographic coverage.
Answer, pranav amin
I think we look at portfolio again. Right now, our portfolio is fine, but in the next couple of quarters, we hope to strengthen this as well. So it's basically just been sharper execution and focused brands and priority markets. Maulik: Understood. Sir, can you help us with the breakup of how much the growth has been from new products, volumes and pricing? Would that be possible?
Answer, g krishnan
G. Krishnan: See, we don't divulge that. But this quarter, we have seen volume-led growth apart from price and new products. So directionally, I would say that it is almost 50- 50 between price and volume because new launches. Page 10of 13 Alembic Pharmaceuticals Limited November 04, 2026 Maulik: Okay. Okay. And my second question is, sir, regarding the DifGen Pharmaceuticals strategic collaboration that we have done. So what is the terms?
Answer, pranav amin
Pranav Amin: Yes. So it's a licensing deal, but we've combined instead of a one-off like we put a lot of licensing deal, but we've just done it as a basket approach because they had a very interesting portfolio of products, and they don't have any front-end presence. S o we have tied up about 20-plus products from them. This is all licensing deal where we do a profit share, and then they do the manufacturing or mostly some we do the manufacturing. And these are interesting. I think one of the reasons why we did it is because they have some capability that we don't. So the transdermal patches, they have some complex injectables, which we are also doing.
Answer, pranav amin
They also have a few other dosage forms, which we are not present in, which will give a good addition to our portfolio. And they have a lot of FTFs and day- 1 launches as well.
Answer, pranav amin
Pranav Amin: Yes. So let me take the first one first. So I said actually in my opening statement, I did say that with the U.S., what we expect over the next 18 months or so is that we have almost 30 products that are going to get launched. Out of those 30 products, roughly about a 1/4 of them will either be a shared Day 1 or a FTF opportunity. So these are interesting products that we see, and that's what we feel that they will give growth. You asked about the existing business. In terms of derm and ophthalmic, ophthalmic is a very good business for us.
Answer, pranav amin
This Q1 of this year, we -- actually Q4 of last year and Q1 is we had a line shutdown. We were increasing the capacity of our line. So that took a minor blip. But on ophthalmics, I can get you the data offline to that, but I'm pretty sure we'll be the 1 or 2 in most of the ophthalmics that we are present, and we have a very strong franchise that we built on the ophthalmic side. Derm also, we managed to get good market share on the derm and it's a high EBITDA business for us. However, having said that, derm is a little more competitive Page 11of 13 Alembic Pharmaceuticals Limited November 04, 2026 compared to the ophthalmic space. So that is existing.
Answer, pranav amin
In terms of the second question in crude and the impact, what we've seen is that all the costs have gone up due to this volatility crude and all the volatility in the world. It's kind of balanced out by the currency depreciation. So those have kind of balanced each other out for us during the quarter. In terms of the FTF portfolio, as I mentioned, is we have a decent pipeline moving forward, almost 30 products that we launched and about a four th of them will be either FTF or Day 1.
Question
Sidharth Negandhi: Very useful. And just to clarify, the DifGen one will be where they will manufacture and you will sell, right? Or are you looking at a licensing where you will also use your manufacturing capability? Sorry, just to clarify.
Answer, pranav amin
Pranav Amin: So this is all developed by them. Most of it is all manufactured by them. Maybe some we may do contract manufacturing, but most of it is manufactured by them as well. And all the marketing and front end will be done by us.
Answer, pranav amin
Pranav Amin: So Foram, what we have done is we've not really disclosed product-wise. We just talked about Alembic Therapeutics, which has about 4 products right now. We've not disclosed the prescription count. On Pivya, it is there. It is still, as I mentioned earlier to the earlier question from somebody that amongst the 3 of them, NUVESSA, NUVETEST, and then Pivya. NUVESSA and NUVETEST is having faster ramp-up because those are existing products. So we've been able to get more prescriptions on those 2 products.
Answer, pranav amin
Pivya is a new product. So there is a little bit of a J-shaped curve that we will see. But we are confident that gradually, those prescriptions are rising. And in the second half, going to the -- by the start of the next year, we should see Pivya also contributing meaningfully.
Question
Foram Parekh: Sure. And a related question to the U.S. market. So since we have given a guidance of 18 to 24 months that on FY27 high growth, we still expect growth in FY28. So if you can give us some more clarity on the growth, whether you'll expect single-digit growth or double-digit growth in FY28?
Answer, pranav amin
Pranav Amin: So I think you're right, this year will be a high base growth for us. I think next year, we're still confident to grow on this. I think it will be close to mid like about 10% to 12% kind of a growth definitely we can see next year if all these launches pan out well.
Question
Foram Parekh: Sure. That's helpful. And my third question is on margins. So in our opening remarks, we mentioned that gross margin expansion is getting cascaded to EBITDA level. So because in this Page 12of 13 Alembic Pharmaceuticals Limited November 04, 2026 quarter, we had a high gross margin of around 74%, and that's cascaded to EBITDA margin around 21%. And we are maintaining our guidance of around 70% to 74%. And prior to this exclusivity product, our gross margin has been around 70% to 72%, which has led to almost 16% kind of EBITDA margin. So going forward from FY2 8 onwards, I mean do we stay in the same range? Or is there anywhere we go back to pre-COVID levels of 77% kind of gross
Answer, g krishnan
G. Krishnan: See, I think there are 2 aspects you are touching upon, right? One is gross margin, we believe it will be in the range of 70% to 75%. That's the normal range that we are working on. If there are a few products that can push up the margins, that's something that we will take it as it comes, right? But when you look at the EBITDA margin, gross margin flowing through to the EBITDA margin, I think there are a few levers that will pull us through closer to 20%. One is, of course, the operating leverage as we have seen last quarter -- since last quarter, we've been saying that the utilization of the existing facilities are -- have ramped up already, and we have good visibility of that continuing in the near future. So that should help us add a good amount of operating leverage coming from the existing facilities.
Answer, g krishnan
Second is you should also remember that the current EBITDA margin profile includes a bit of drag from the U.S. branded business. And as Pranav said that beginning next year, we should be seeing that breakeven, right? And that should also start diluting the overall margin profile, which should help us get closer to the 20%.
Question
Foram Parekh: Sure. So we do envisage 20% kind of EBITDA margin in the near term, right, FY2 8, '29?
Answer, pranav amin
Pranav Amin: Yes, we would like to go towards those kind of margins.
Answer, isha lamba
Isha Lamba: Thank you, everyone, for joining the call. If you have any further questions, please reach out to the IR team. Thank you.
Questions about this call
- When was the Alembic Pharmaceuticals Q2 FY27 earnings call transcript filed?
- Alembic Pharmaceuticals filed the transcript with the exchange on 10 Nov 2026. This page is built from that transcript.
- What does this page list?
- 64 statements from the transcript across 9 topics, 37 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 19 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.